Axio Biosolutions, based in Bengaluru, has announced that it has received CE Certification from Europe for its next generation advanced wound-care product range, MaxioCel. The regulatory approval paves the path for Axio to tap into a fast growing $14 billion advanced wound-care market, globally. 

This next-generation advanced wound-care dressing, MaxioCel is based on Bioactive Microfiber Gelling technology that accelerates healing through quicker granulation. It also provides comfort and has shown faster healing on chronic wounds, such as pressure ulcers, diabetic foot ulcers, venous leg ulcers, cavity wounds, skin abrasions, donor sites and post-operative surgical wounds during clinical studies.

With more than 100,000 units shipped since its launch 18 months ago, MaxioCel has had a huge impact in Indian market.

Dr Raghuram Sekhar, Consultant Vascular and Endovascular Surgeon, Kokilaben Dhirubhai Ambani Hospital, Mumbai who has been a long term user of Maxiocel affirms, “MaxioCel is a unique and advanced wound care dressing material. In different kind of cases that we used it, we witnessed rapid granulation and overall wound improvement while keeping the patients comfortable.”

The CE approval will now help Axio with access to the second largest global market for advanced wound-care products. As part of its strategic plans, Axio will soon be launching MaxioCel in 15+ countries in Europe including reimbursement markets with multi-million revenues in this year itself.

Responding to the CE certification and subsequent access to the European market, Leo Mavely, Founder and CEO, Axio Biosolutions said, “Since its launch, MaxioCel has made a huge impact on patient lives and the medical fraternity in India. We are excited to have the opportunity to extend this innovative and highly effective solution on a global level.”